SAN DIEGO and VANCOUVER, British Columbia, Sept. 30, 2013 /PRNewswire/ -- GenomeDx Biosciences Inc, announced today it has closed a Series B financing round led by Merck Global Health Innovation Fund (GHIF) and other investors including Baird Capital Partners, aeris CAPITAL AG and CD Ventures. This additional capital will be used to further expand the commercialization of the Decipher™ prostate cancer test, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools.
"Together with our collaborators in the prostate cancer community we have developed a robust package of clinical validation and clinical utility data supporting the use of Decipher in clinical practice," said Doug Dolginow, M.D., CEO of GenomeDx. "The funding of GenomeDx by these accomplished, visionary investors is instrumental to achieving our goal of using genomic information to transform the treatment and management of men diagnosed with prostate cancer."
The Decipher™ prostate cancer test directly measures a patient's biological risk of developing metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient's tumor - information distinct from that provided by PSA and other clinical tools. Already tested in over 2,000 patients, Decipher continues to demonstrate in clinical studies that it can accurately predict aggressive disease and direct treatment decisions for men with prostate cancer.
Decipher™ is available to eligible US patients through their physicians and as a part of GenomeDx's ongoing program of clinical studies.
About GenomeDx Biosciences
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that direct treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. GenomeDx has developed the Decipher™ prostate cancer classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia. More information is available at www.genomedx.com.
SOURCE GenomeDx Biosciences